Authors: Schlenk, RF Frohling, S Del Valle, F Hartmann, F Glasmacher, A Fischer, JT Grimminger, W Weber, C Weber, W Gunzer, U Gotze, K Waterhouse, C Benner, A Dohner, K Haas, R Ho, AD Dohner, H

Citation: Rf. Schlenk et al., Stratification of postremission therapy in patients with acute myeloid leukemia <= 60 years according to the karyotype: Results of the German multicenter treatment trials AML HD93 and AML HD98-A, HEMAT BLOOD, 40, 2001, pp. 470-476

Authors: Frohling, S Schlenk, RF Del Valle, F Hartmann, F Glasmacher, A Fischer, JT Grimminger, W Weber, C Weber, W Gunzer, U Gotze, K Dohner, K Haas, R Ho, AD Dohner, H

Citation: S. Frohling et al., Chemotherapy and all-trans retinoic acid in patients > 60 years with acutemyeloid leukemia: First results of the multicenter treatment trial AML HD98-B, HEMAT BLOOD, 40, 2001, pp. 604-608

Authors: Colmenares, W Tadeo, F Granado, E Perez, O Del Valle, F

Citation: W. Colmenares et al., H-2 guaranteed cost control of discrete linear systems, MATH PROB E, 6(5), 2000, pp. 425-437